Compass Research LLC

1. Eli Lilly and Company $7,216,498 134 payments
2. Eisai Inc. $4,959,583 217 payments
3. Allergan Inc. $932,954 49 payments
4. Biogen, Inc. $774,492 17 payments
5. Sunovion Pharmaceuticals Inc. $692,224 80 payments
6. E.R. Squibb & Sons, L.L.C. $513,091 6 payments
7. Roche TCRC, Inc. $385,977 49 payments
8. Boehringer Ingelheim Pharmaceuticals, Inc. $200,921 2 payments
9. Genentech, Inc. $195,465 36 payments
10. Pfizer Inc. $141,295 29 payments

1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $3,779,261 121 payments
2. Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study $3,345,494 21 payments
3. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $1,662,391 22 payments
4. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $1,075,515 8 payments
5. An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease $602,836 40 payments
6. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $478,221 27 payments
7. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $423,727 20 payments
8. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $416,130 39 payments
9. Phase II Study in Early Stage Parkinson S Disease Patients $385,977 49 payments
10. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $378,628 4 payments

1. Other $36,365 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.